Analysts at Needham downgraded NetApp, Inc. (NTAP) from ‘Buy‘ to ‘Hold‘ in a research report issued to clients on Thursday.
On valuation measures, NetApp Inc. stock it’s trading at a forward P/E multiple of 10.27x, and at a multiple of 16.36x this year’s estimated earnings. The t-12-month revenue at NetApp Inc. is $6.23 billion. NTAP ‘s ROE for the same period is 16.76%.
Shares of the $9.69 billion market cap company are up 5.89% year-over-year ; down 14% year-to-date.
NetApp Inc., currently with a median Wall Street price target of $39 and a high target of $48, dropped $4.26 to $31.08 in recent trading.
The chart below shows where the equity has traded over the past 52-weeks.
Lumber Liquidators Holdings, Inc. (LL) was downgraded from ‘Outperform‘ to ‘Market Perform‘ at Raymond James.
Shares have traded today between $20.97 and $21.94 with the price of the stock fluctuating between $20.97 to $84.77 over the last 52 weeks.
Lumber Liquidators Holdings Inc. shares are currently changing hands at 14x this year’s forecasted earnings, compared to the industry’s 34.51x earnings multiple. Ticker has a t-12 price/sales ratio of 0.64. EPS for the same period registers at $1.54.
Shares of LL have lost $3.72 to $21.55 in mid-day trading on Thursday, giving it a market cap of roughly $584 million. The stock traded as high as $84.77 in May 27, 2014.
Mizuho reported on Thursday that they have lowered their rating for Bruker Corporation (BRKR). The firm has downgraded BRKR from ‘Buy‘ to ‘Neutral‘ and set its price target to $22.
Bruker Corp. recently traded at $19.32, a loss of $2.89 over Wednesday’s closing price. The name has a current market capitalization of $3.26 billion.
Sarepta Therapeutics, Inc. (SRPT) had its rating lowered from ‘Buy‘ to ‘Neutral‘ by analysts at BofA/Merrill (BAC) on Thursday. Currently there are 8 analysts that rate SRPT a ‘Buy‘ versus 8 rating it a ‘Hold‘.
SRPT was down $1.87 at $24.37 in mid-day trade, moving within a 52-week range of $11.33 to $35.45. The name, valued at $1.01 billion, opened at $24.85.
On valuation measures, Sarepta Therapeutics Inc. shares have a t-12 price/sales ratio of 296.56. EPS for the same period registers at ($4.13).
Open Text Corporation (OTEX) rating of ‘Buy’ was reiterated today at The Benchmark Company with a price target decrease of $55 from $62 (versus a $49.00 previous close).